JP2012517482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517482A5 JP2012517482A5 JP2011550274A JP2011550274A JP2012517482A5 JP 2012517482 A5 JP2012517482 A5 JP 2012517482A5 JP 2011550274 A JP2011550274 A JP 2011550274A JP 2011550274 A JP2011550274 A JP 2011550274A JP 2012517482 A5 JP2012517482 A5 JP 2012517482A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- biopharmaceutical
- site
- disease
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 98
- 229960000074 biopharmaceutical Drugs 0.000 claims description 54
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 33
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 33
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 33
- 210000001519 tissue Anatomy 0.000 claims description 33
- 230000002093 peripheral effect Effects 0.000 claims description 29
- 208000014674 injury Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 230000002792 vascular Effects 0.000 claims description 16
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 14
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 14
- 210000000845 cartilage Anatomy 0.000 claims description 14
- 208000037816 tissue injury Diseases 0.000 claims description 14
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 13
- 235000018102 proteins Nutrition 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 208000026062 Tissue disease Diseases 0.000 claims description 10
- 230000007547 defect Effects 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 238000007910 systemic administration Methods 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims description 6
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 claims description 6
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims description 6
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 6
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 claims description 6
- 101710204283 Growth/differentiation factor 7 Proteins 0.000 claims description 6
- 239000003124 biologic agent Substances 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 4
- 206010007710 Cartilage injury Diseases 0.000 claims description 4
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 4
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 claims description 4
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 claims description 4
- 210000001188 articular cartilage Anatomy 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 208000015100 cartilage disease Diseases 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 210000003041 ligament Anatomy 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 210000001258 synovial membrane Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 2
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 2
- 241001260012 Bursa Species 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 2
- 238000012752 Hepatectomy Methods 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 201000009859 Osteochondrosis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010038895 Retinal scar Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 238000012386 biopharmaceutical delivery Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000018180 degenerative disc disease Diseases 0.000 claims description 2
- 208000018138 dendritic cell deficiency Diseases 0.000 claims description 2
- 210000004268 dentin Anatomy 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000000281 joint capsule Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 210000002161 motor neuron Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000003239 periodontal effect Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 230000000770 proinflammatory effect Effects 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 230000004565 tumor cell growth Effects 0.000 claims description 2
- 210000000264 venule Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15190909P | 2009-02-12 | 2009-02-12 | |
| US61/151,909 | 2009-02-12 | ||
| PCT/US2010/024106 WO2010093925A2 (en) | 2009-02-12 | 2010-02-12 | PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014128940A Division JP2014169336A (ja) | 2009-02-12 | 2014-06-24 | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012517482A JP2012517482A (ja) | 2012-08-02 |
| JP2012517482A5 true JP2012517482A5 (enExample) | 2013-03-07 |
| JP5819733B2 JP5819733B2 (ja) | 2015-11-24 |
Family
ID=42105903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550274A Expired - Fee Related JP5819733B2 (ja) | 2009-02-12 | 2010-02-12 | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
| JP2014128940A Pending JP2014169336A (ja) | 2009-02-12 | 2014-06-24 | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014128940A Pending JP2014169336A (ja) | 2009-02-12 | 2014-06-24 | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20100204123A1 (enExample) |
| EP (1) | EP2396025A2 (enExample) |
| JP (2) | JP5819733B2 (enExample) |
| CN (1) | CN102369016A (enExample) |
| AU (1) | AU2010213575B2 (enExample) |
| CA (1) | CA2752157A1 (enExample) |
| SG (2) | SG2014010680A (enExample) |
| WO (1) | WO2010093925A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2441466T3 (da) | 2004-04-13 | 2014-10-27 | St Vincents Hosp Sydney | MIC-1-inhiberende middel |
| WO2009137613A2 (en) * | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| CN117986363A (zh) | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| BR112021002703A2 (pt) | 2018-08-31 | 2021-05-11 | Timothy A. Bertram | composições compreendendo vesículas derivadas de células e usos das mesmas |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| AU666291B2 (en) | 1990-06-15 | 1996-02-08 | Carnegie Institution Of Washington | Gdf-1 |
| US5849686A (en) | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
| US5674844A (en) | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6949505B1 (en) | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
| US5656593A (en) | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US6506729B1 (en) | 1991-03-11 | 2003-01-14 | Curis, Inc. | Methods and compositions for the treatment and prevention of Parkinson's disease |
| CZ282231B6 (cs) * | 1991-06-05 | 1997-06-11 | The Procter And Gamble Company | Prostředek na generování nového růstu kosti v savci |
| US5693615A (en) * | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| KR100259827B1 (ko) | 1991-11-04 | 2000-06-15 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법 |
| CA2129820C (en) | 1992-02-12 | 2003-06-17 | Helge Neidhardt | Dna sequences encoding novel growth/differentiation factors |
| WO1994010203A2 (en) | 1992-11-03 | 1994-05-11 | Creative Biomolecules, Inc. | Op-3-induced morphogenesis |
| WO1994015966A1 (en) | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Growth differentiation factor-9 |
| EP0690871A4 (en) | 1993-01-12 | 1999-10-20 | Univ Johns Hopkins Med | GROWTH DIFFERENTIATION FACTOR-5 |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| EP0698094B1 (en) | 1993-05-12 | 2004-02-04 | Genetics Institute, LLC | Bmp-11 compositions |
| ATE265529T1 (de) | 1993-05-12 | 2004-05-15 | Inst Genetics Llc | Bmp-10 zusammensetzungen |
| US5447725A (en) | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
| JPH09503903A (ja) | 1993-07-09 | 1997-04-22 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−６ |
| EP0725796A4 (en) | 1993-10-08 | 1999-12-01 | Univ Johns Hopkins | Growth differentiation factor-10 |
| JP3300500B2 (ja) | 1993-10-12 | 2002-07-08 | 新日本製鐵株式会社 | 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法 |
| DE4334646C1 (de) | 1993-10-12 | 1994-09-29 | Quinting Friedhelm | Durchsichtige Analog-Zeituhr |
| EP0733109B9 (en) | 1993-12-07 | 2006-07-05 | Genetics Institute, LLC | Bmp-12, bmp-13 and tendon-inducing compositions thereof |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| IL114397A0 (en) | 1994-07-01 | 1995-10-31 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF-beta-family |
| DE69534468T2 (de) | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| WO1996014335A1 (en) | 1994-11-07 | 1996-05-17 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services | Cartilage-derived morphogenetic proteins |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| ATE493141T1 (de) * | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| WO1999015191A2 (en) * | 1997-09-19 | 1999-04-01 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Cytokines having neurotrophic activity |
| US20030170213A1 (en) * | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
| US7147839B2 (en) * | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
| JP3762222B2 (ja) | 1998-10-07 | 2006-04-05 | ストライカー・コーポレーション | 改変型ＴＧＦ−βスーパーファミリータンパク質 |
| US6846906B1 (en) | 1998-10-07 | 2005-01-25 | Stryker Corporation | Modified proteins of the TGF-β superfamily, including morphogenic proteins |
| US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| US20030104977A1 (en) * | 2000-03-31 | 2003-06-05 | Ugo Ripamonti | Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| BR0209198A (pt) * | 2001-04-26 | 2004-06-08 | Control Delivery Sys Inc | Métodos de sìntese de compostos contendo fenol |
| US8154581B2 (en) | 2002-10-15 | 2012-04-10 | Revolutionary Concepts, Inc. | Audio-video communication system for receiving person at entrance |
| DK1677735T3 (da) * | 2003-10-17 | 2014-10-27 | Joslin Diabetes Center Inc | Fremgangsmåder og sammensætninger til modulering af adipocytfunktion |
| CA2561809A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| EP1750743A4 (en) * | 2004-04-29 | 2009-07-08 | Glaxosmithkline Zagreb | ORAL PREPARATIONS CONTAINING BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF METABOLIC BONE DISEASES |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| AU2005251741B2 (en) * | 2004-06-03 | 2009-09-24 | Genera Istrazivanja D.O.O. | Insulin-independent, bone morphogenetic protein (BMP)-mediated uptake of blood glucose by peripheral cells and tissues |
| US7901395B2 (en) * | 2005-08-16 | 2011-03-08 | Borden Jonathan R | Catheter having staggered lumens and method |
| ATE543833T1 (de) | 2005-12-22 | 2012-02-15 | Janssen Biotech Inc | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen |
| EP2144624A1 (en) * | 2007-05-15 | 2010-01-20 | Stryker Corporation | Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof |
| WO2010117047A1 (ja) | 2009-04-10 | 2010-10-14 | 株式会社ニコン | 光学材料、光学素子、及びその製造方法 |
| JP2011211450A (ja) | 2010-03-30 | 2011-10-20 | Victor Co Of Japan Ltd | 立体映像表示装置、立体映像撮像装置および立体映像表示方法 |
| US9507084B2 (en) | 2010-12-03 | 2016-11-29 | Ofs Fitel, Llc | Single-mode, bend-compensated, large-mode-area optical fibers designed to accomodate simplified fabrication and tighter bends |
| US8886307B2 (en) | 2012-01-30 | 2014-11-11 | Medtronic, Inc. | Adaptive cardiac resynchronization therapy |
| KR101851912B1 (ko) | 2012-06-07 | 2018-04-24 | 아사히 가세이 일렉트로닉스 가부시끼가이샤 | 위치 검출 장치 |
| US9298469B2 (en) | 2012-06-15 | 2016-03-29 | International Business Machines Corporation | Management of multiple nested transactions |
| US9405290B1 (en) | 2013-01-17 | 2016-08-02 | Kla-Tencor Corporation | Model for optical dispersion of high-K dielectrics including defects |
| JP6154215B2 (ja) | 2013-06-28 | 2017-06-28 | 株式会社日立国際電気 | 半導体装置の製造方法、基板処理装置およびプログラム |
| US9170581B2 (en) | 2013-09-30 | 2015-10-27 | Crown Equipment Limited | Industrial vehicles with overhead light based localization |
| JP6541301B2 (ja) | 2014-03-28 | 2019-07-10 | キヤノン株式会社 | ロボット装置、ロボット装置の制御方法、ロボット制御プログラム、及び記録媒体 |
| US9411440B2 (en) | 2014-08-22 | 2016-08-09 | Qualcomm Incorporated | Digital ultrasonic emitting base station |
| US9407762B2 (en) | 2014-10-10 | 2016-08-02 | Bank Of America Corporation | Providing enhanced user authentication functionalities |
| US9412814B2 (en) | 2014-12-24 | 2016-08-09 | Taiwan Semiconductor Manufacturing Co., Ltd. | Structure and formation method of FinFET device |
-
2010
- 2010-02-12 US US12/705,259 patent/US20100204123A1/en not_active Abandoned
- 2010-02-12 SG SG2014010680A patent/SG2014010680A/en unknown
- 2010-02-12 WO PCT/US2010/024106 patent/WO2010093925A2/en not_active Ceased
- 2010-02-12 CA CA2752157A patent/CA2752157A1/en not_active Abandoned
- 2010-02-12 EP EP10705489A patent/EP2396025A2/en not_active Withdrawn
- 2010-02-12 CN CN2010800147650A patent/CN102369016A/zh active Pending
- 2010-02-12 JP JP2011550274A patent/JP5819733B2/ja not_active Expired - Fee Related
- 2010-02-12 AU AU2010213575A patent/AU2010213575B2/en not_active Ceased
- 2010-02-12 SG SG2011057668A patent/SG173632A1/en unknown
-
2012
- 2012-04-11 US US13/444,282 patent/US20120258917A1/en not_active Abandoned
- 2012-11-19 US US13/680,381 patent/US20130288966A1/en not_active Abandoned
-
2013
- 2013-07-18 US US13/945,317 patent/US20140187486A1/en not_active Abandoned
-
2014
- 2014-02-21 US US14/186,545 patent/US20140336595A1/en not_active Abandoned
- 2014-06-24 JP JP2014128940A patent/JP2014169336A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5607176B2 (ja) | 新規ペプチドおよびその用途 | |
| TWI257307B (en) | Pharmaceutical composition for cardiac tissue repair | |
| AU2010213575B2 (en) | Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease | |
| JP5815206B2 (ja) | Ｆｇｆ−１８を用いた軟骨障害の治療 | |
| JP6363952B2 (ja) | 成長ホルモン断片の使用 | |
| US20210206820A1 (en) | Targeting anabolic drugs for accelerated fracture repair | |
| RS52710B (sr) | Lečenje poremećaja hrskavice sa fgf-18 | |
| RU2017140049A (ru) | Композиции для лечения поражений тканей | |
| CN117957004A (zh) | 用于整形外科领域的包含透明质酸钠和氨基酸的组合物 | |
| JP2001131086A (ja) | エンドセリンを含む結合組織修復促進組成物および該組成物の調製におけるエンドセリンの使用 | |
| JP2012517483A5 (enExample) | ||
| WO2022085791A1 (ja) | 老化により機能低下した骨格筋の筋機能改善剤 | |
| Kiani et al. | Exploring kartogenin: advances in therapeutics and signaling mechanisms for musculoskeletal regeneration | |
| JP5819734B2 (ja) | ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法 | |
| JP5629940B2 (ja) | 関節疾患治療用の組み合わせ製剤 | |
| RU2822321C1 (ru) | Способ лечения остеоартрита коленного сустава | |
| JP2001122799A (ja) | プレイオトロフィンを含む結合組織修復促進組成物および該組成物の調製におけるプレイオトロフィンの使用 | |
| WO2017011762A1 (en) | Treating rotator cuff conditions | |
| JP4440412B2 (ja) | 腫瘍転移抑制剤 | |
| Kim et al. | Injection materials for the larynx | |
| AU2013206499A1 (en) | Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease |